KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab

by Bando, H, Yoshino, T, Tsuchihara, K, Ogasawara, N, Fuse, N, Kojima, T, Tahara, M, Kojima, M, Kaneko, K, Doi, T, Ochiai, A, Esumi, H, Ohtsu, A
Published 2011

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

by Doi, T, Takiuchi, H, Ohtsu, A, Fuse, N, Goto, M, Yoshida, M, Dote, N, Kuze, Y, Jinno, F, Fujimoto, M, Takubo, T, Nakayama, N, Tsutsumi, R
Published 2012

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

by Kawamoto, Y, Tsuchihara, K, Yoshino, T, Ogasawara, N, Kojima, M, Takahashi, M, Ochiai, A, Bando, H, Fuse, N, Tahara, M, Doi, T, Esumi, H, Komatsu, Y, Ohtsu, A
Published 2012

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

by Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T
Published 2013

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

by Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T
Published 2014